Published in Antimicrob Agents Chemother on April 07, 2008
Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses (2010) 0.93
The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B. J Clin Transl Hepatol (2013) 0.78
Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling. Clin Pharmacol Ther (2011) 0.77
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm (1977) 4.22
Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology (2003) 3.30
The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med (2007) 3.20
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (2002) 2.83
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 2.54
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 1.76
Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis (2003) 1.63
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology (2005) 1.46
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother (2004) 1.44
Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol (1999) 1.33
Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 1.32
Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother (2006) 1.29
Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med (1984) 1.22
The pathology of malabsorption: current concepts. Histopathology (2007) 1.06
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? Neth J Med (2006) 1.04
Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis (2007) 1.03
Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis (2001) 0.96
Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clin Pharmacokinet (2005) 0.94
Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol (2006) 0.88
Progress on the control of hepatitis B infection through immunisation. Gut (1993) 0.84
Entecavir: a review of its use in chronic hepatitis B. Drugs (2006) 0.79
Optimizing management strategies in special patient populations. Am J Gastroenterol (2006) 0.78
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology (2011) 2.10
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology (2011) 1.83
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol (2013) 1.69
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care (2013) 1.58
Hierarchical MnMoO(4)/CoMoO(4) heterostructured nanowires with enhanced supercapacitor performance. Nat Commun (2011) 1.55
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol (2013) 1.45
A possible new disinfection by-product--2-chloro-5-oxo-3-hexene diacyl chloride (COHC)--in formation of MX by chlorinating model compounds. Water Res (2002) 1.39
Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol (2012) 1.32
A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One (2012) 1.27
Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J (2008) 1.27
Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother (2004) 1.23
A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment. PLoS One (2012) 1.20
Axonal fiber terminations concentrate on gyri. Cereb Cortex (2011) 1.18
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis (2012) 1.18
Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. J Ethnopharmacol (2013) 1.17
Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. J Clin Pharmacol (2010) 1.13
Genome-wide analysis of heat shock transcription factor families in rice and Arabidopsis. J Genet Genomics (2008) 1.13
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther (2013) 1.12
Effect of carbon matrix dimensions on the electrochemical properties of Na3V2(PO4)3 nanograins for high-performance symmetric sodium-ion batteries. Adv Mater (2014) 1.11
A novel chemometric method for the prediction of human oral bioavailability. Int J Mol Sci (2012) 1.09
Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother (2009) 1.09
2-Hydr-oxy-6,6-dimethyl-bicyclo-[3.1.1]heptane-2-carboxylic acid. Acta Crystallogr Sect E Struct Rep Online (2009) 1.07
16-Isopropyl-5,9-dimethyltetra-cyclo-[10.2.2.0.0]hexa-dec-15-ene-5,14-dicarboxylic acid ethanol hemisolvate. Acta Crystallogr Sect E Struct Rep Online (2009) 1.06
Electrospun ultralong hierarchical vanadium oxide nanowires with high performance for lithium ion batteries. Nano Lett (2010) 1.06
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl (2012) 1.05
Effect of Vitamin E supplementation on semen quality and the testicular cell membranal and mitochondrial antioxidant abilities in Aohan fine-wool sheep. Anim Reprod Sci (2009) 1.03
Modeling and simulation of adherence: approaches and applications in therapeutics. AAPS J (2005) 1.02
Nanoscroll buffered hybrid nanostructural VO2 (B) cathodes for high-rate and long-life lithium storage. Adv Mater (2013) 1.02
BLogo: a tool for visualization of bias in biological sequences. Bioinformatics (2008) 1.01
Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug. J Pharm Sci (2013) 1.00
Crystal structure of a mono- and diacylglycerol lipase from Malassezia globosa reveals a novel lid conformation and insights into the substrate specificity. J Struct Biol (2012) 1.00
Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform (2013) 1.00
Synergistic interaction between redox-active electrolyte and binder-free functionalized carbon for ultrahigh supercapacitor performance. Nat Commun (2013) 1.00
Content differences for abstract and concrete concepts. Cogn Sci (2005) 0.99
Deciphering the combination principles of Traditional Chinese Medicine from a systems pharmacology perspective based on Ma-huang Decoction. J Ethnopharmacol (2013) 0.98
Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther (2011) 0.97
Study on the precipitation reaction between baicalin and berberine by HPLC. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.96
Enzymatically depolymerized alginate oligomers that cause cytotoxic cytokine production in human mononuclear cells. Biosci Biotechnol Biochem (2003) 0.95
MiR-206-mediated dynamic mechanism of the mammalian circadian clock. BMC Syst Biol (2011) 0.95
Cucumber-like V2O5/poly(3,4-ethylenedioxythiophene)&MnO2 nanowires with enhanced electrochemical cyclability. Nano Lett (2013) 0.94
Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clin Pharmacokinet (2005) 0.94
Nanowire templated semihollow bicontinuous graphene scrolls: designed construction, mechanism, and enhanced energy storage performance. J Am Chem Soc (2013) 0.94
Nanowire electrodes for electrochemical energy storage devices. Chem Rev (2014) 0.93
Emissions of air pollutants from household stoves: honeycomb coal versus coal cake. Environ Sci Technol (2004) 0.93
A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease. Evid Based Complement Alternat Med (2012) 0.92
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol (2015) 0.92
Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. Chem Res Toxicol (2011) 0.90
Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2008) 0.90
A large-scale association study for nanoparticle C60 uncovers mechanisms of nanotoxicity disrupting the native conformations of DNA/RNA. Nucleic Acids Res (2012) 0.90
Structural determination of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics methods. Int J Mol Sci (2011) 0.90
Assessment of estrogenic contamination and biological effects in Lake Taihu. Ecotoxicology (2011) 0.90
Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer. Genes Cancer (2011) 0.89
Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol (2006) 0.88
In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Antimicrob Agents Chemother (2010) 0.88
Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother (2002) 0.88
Scleritodermin A, a cytotoxic cyclic peptide from the lithistid sponge Scleritoderma nodosum. J Nat Prod (2004) 0.88
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther (2014) 0.88
A systems biology approach to understanding the mechanisms of action of chinese herbs for treatment of cardiovascular disease. Int J Mol Sci (2012) 0.88
Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. Am J Health Syst Pharm (2010) 0.87
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antivir Ther (2013) 0.87
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS (2005) 0.87
Determination of organophosphorus pesticides in peanut oil by dispersive solid phase extraction gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.87
Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants. Ther Clin Risk Manag (2011) 0.87
Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther (2015) 0.86
Two TPX2-dependent switches control the activity of Aurora A. PLoS One (2011) 0.86
Quantitative determination of BMS-378806 in human plasma and urine by high-performance liquid chromatography/tandem mass spectrometry. J Sep Sci (2007) 0.86
Risk assessment on disinfection by-products of drinking water of different water sources and disinfection processes. Environ Int (2006) 0.85
Ultrasonic nebulization extraction-heating gas flow transfer-headspace single drop microextraction of essential oil from pericarp of Zanthoxylum bungeanum Maxim. J Chromatogr A (2011) 0.85
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus. Clin Drug Investig (2014) 0.85
Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice. Cancer Lett (2011) 0.85
Hierarchical mesoporous perovskite La0.5Sr0.5CoO2.91 nanowires with ultrahigh capacity for Li-air batteries. Proc Natl Acad Sci U S A (2012) 0.85
Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. J Clin Pharmacol (2010) 0.85
Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol (2007) 0.85
Assessment of toxic interactions of heavy metals in multi-component mixtures using sea urchin embryo-larval bioassay. Toxicol In Vitro (2010) 0.84
Dynamic mechanisms for pre-miRNA binding and export by Exportin-5. RNA (2011) 0.84
Influence of P-glycoprotein on embryotoxicity of the antifouling biocides to sea urchin (Strongylocentrotus intermedius). Ecotoxicology (2011) 0.84
Dynamic communication between androgen and coactivator: mutually induced conformational perturbations in androgen receptor ligand-binding domain. Proteins (2011) 0.84
Investigation of binding features: effects on the interaction between CYP2A6 and inhibitors. J Comput Chem (2010) 0.84
In silico prediction of estrogen receptor subtype binding affinity and selectivity using statistical methods and molecular docking with 2-arylnaphthalenes and 2-arylquinolines. Int J Mol Sci (2010) 0.84
Discovery of estrogen receptor modulators: a review of virtual screening and SAR efforts. Expert Opin Drug Discov (2010) 0.83
Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients. Antimicrob Agents Chemother (2011) 0.83
Distribution of the functional MDR1 C3435T polymorphism in the Han population of China. Swiss Med Wkly (2006) 0.83
Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve. Pharmacotherapy (2013) 0.83
Pharmacokinetic-pharmacodynamic modelling of magnesium plasma concentration and blood pressure in preeclamptic women. Clin Pharmacokinet (2002) 0.83
Can graphene oxide cause damage to eyesight? Chem Res Toxicol (2012) 0.83
System-level multi-target drug discovery from natural products with applications to cardiovascular diseases. Mol Divers (2014) 0.83
Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens (2002) 0.83
Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication. Integr Biol (Camb) (2013) 0.83
Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2009) 0.83
Predicting the interface morphologies of silicon films on arbitrary substrates: application in solar cells. ACS Appl Mater Interfaces (2013) 0.83
Molecular basis for substrate selectivity of a mono- and diacylglycerol lipase from Malassezia globosa. Biochem Biophys Res Commun (2012) 0.83
Rational synthesis of silver vanadium oxides/polyaniline triaxial nanowires with enhanced electrochemical property. Nano Lett (2011) 0.83
Theoretical study of the mechanism of acetaldehyde hydroxylation by compound I of CYP2E1. J Phys Chem B (2006) 0.82
Macrophage migration inhibitory factor (MIF) in chinese amphioxus as a molecular marker of immune evolution during the transition of invertebrate/vertebrate. Dev Comp Immunol (2004) 0.82
A Bayesian population PBPK model for multiroute chloroform exposure. J Expo Sci Environ Epidemiol (2009) 0.82
Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacol (2008) 0.82
A classification study of respiratory Syncytial Virus (RSV) inhibitors by variable selection with random forest. Int J Mol Sci (2011) 0.82